1. Home
  2. BUUU vs ALLO Comparison

BUUU vs ALLO Comparison

Compare BUUU & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BUUU

BUUU Group Limited Class A Ordinary Share

N/A

Current Price

$12.66

Market Cap

250.8M

ML Signal

N/A

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

N/A

Current Price

$2.44

Market Cap

252.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BUUU
ALLO
Founded
2017
2017
Country
Hong Kong
United States
Employees
16
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.8M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BUUU
ALLO
Price
$12.66
$2.44
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.27
AVG Volume (30 Days)
22.3K
4.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.84
EPS
N/A
N/A
Revenue
N/A
$22,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$347.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.97
$0.86
52 Week High
$20.76
$2.80

Technical Indicators

Market Signals
Indicator
BUUU
ALLO
Relative Strength Index (RSI) 52.90 59.72
Support Level $6.84 $1.01
Resistance Level $19.73 $2.80
Average True Range (ATR) 1.82 0.18
MACD -0.45 -0.01
Stochastic Oscillator 22.79 53.80

Price Performance

Historical Comparison
BUUU
ALLO

About BUUU BUUU Group Limited Class A Ordinary Share

BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: